Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies

Publication Type:

Article

Authors:

Carmen Martin-Alonso, Shervin Tabrizi , Kan Xiong, Timothy Blewett, Sainetra Sridhar, Andjela Crnjac, Sahil Patel, Zhenyi An, Ahmet Bekdemir, Douglas Shea, Shih-Ting Wang, Sergio Rodriguez-Aponte, Christopher A. Naranjo, Justin Rhoades, Jesse D. Kirkpatrick, Heather E. Fleming, Ava P. Amini, Todd R. Golub, J. Christopher Love , Sangeeta N. Bhatia, and Viktor A. Adalsteinsson.

Source:

Science (2024)

URL:

https://www.science.org/doi/10.1126/science.adf2341

Abstract:

Liquid biopsies enable early detection and monitoring of diseases such as cancer, but their sensitivity remains limited by the scarcity of analytes such as cell-free DNA (cfDNA) in blood. Improvements to sensitivity have primarily relied on enhancing sequencing technology ex vivo. We sought to transiently augment the level of circulating tumor DNA (ctDNA) in a blood draw by attenuating its clearance in vivo. We report two intravenous priming agents given 1 to 2 hours before a blood draw to recover more ctDNA. Our priming agents consist of nanoparticles that act on the cells responsible for cfDNA clearance and DNA-binding antibodies that protect cfDNA. In tumor-bearing mice, they greatly increase the recovery of ctDNA and improve the sensitivity for detecting small tumors.


Manuscript (PDF)

Previous
Previous

Targeting and monitoring ovarian cancer invasion with an RNAi and peptide delivery system

Next
Next

Inhalable point-of-care urinary diagnostic platform